titanpharm.com (TTNP): Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Symbol and logo of brand Titan Pharmaceuticals Inc. (TTNP)

Titan Pharmaceuticals (TTNP) develops innovative subcutaneous systems to combat opioid addiction, leveraging proprietary ProNeura technology and strict FDA standards. The business relies on a powerful US tech park that develops solutions for chronic pain therapy. This chart of market price action by the EV/EBITDA multiple is . The stability of the outlook is ensured by the streamlined delivery of specialized polymers through a diversified network of hubs.

TTNP Titan Pharma: Enterprise Value to EBITDA Ratio in the range 07/04/2022 - 11/13/2026

Analytical breakdowns for Titan Pharmaceuticals

- current price and projected stock value:
Stock Price Titan Pharmaceuticals, Inc.|TTNP - Analyst Consensus Forecast
- stock exchange capitalization data:
Market Value Titan Pharmaceuticals, Inc.|TTNP - Value Adjusted for Debt and Cash
- book value of equity indicators:
Net Assets per Single Share Titan Pharmaceuticals|TTNP - Company Net Assets|Market Cap to Net Assets Ratio titanpharm.com|TTNP - Aggregate Business Assets
- debt and solvency information:
Total Debt to Capital Titan Pharmaceuticals|TTNP - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio Titan Pharmaceuticals, Inc.|TTNP - Company Cumulative Indebtedness|Debts to Book Capitalization Titan Pharmaceuticals, Inc.|TTNP - Company Long-Term Debts|Company Short-Term Debt Titan Pharmaceuticals|Quick Liquidity Indicator titanpharm.com
- business earnings and investment ratios data:
TTNP - Final Profit|Expected Profit Titan Pharmaceuticals|TTNP - Market Cap to Net Income|Forward P/E Multiple Titan Pharmaceuticals, Inc.|TTNP - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Titan Pharmaceuticals, Inc.|TTNP - Operating profit EBITDA|Earnings per share for the last twelve months Titan Pharmaceuticals|TTNP - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months titanpharm.com|TTNP - Net earnings per share growth this year|Earnings growth forecast for next year Titan Pharmaceuticals
General company analysis:Titan Pharma TTNP
Product sample of Titan Pharmaceuticals Inc.

To assess the operational resilience of assets, an investor analyzes a business's ability to generate cash flow relative to its total value. In the case of Titan Pharmaceuticals (TTNP), this allows for a comparison between the development costs of addiction therapy implants and actual profitability. Analyzing the EV/EBITDA ratio over a specific time interval eliminates the impact of taxes and debt structure, determining the fair value of the business and the risk of a prolonged capital drawdown.

Competitors of Titan Pharmaceuticals

EV/EBITDA Multiple INDV (Indivior Group)|EV/EBITDA Multiple Collegium Corp COLL|CRON - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation CGC (canopygrowth.com)|High Tide (HITI) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Aurora Cannabis Inc.|Enterprise Value to EBITDA Ratio ACHV|SKYE (skyebioscience.com) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple ANEB|Total Company Value to Operating Income Before Depreciation Ratio intercure.co|Nutriband - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio NSRX (Nasus Pharma Ltd.)|IGC Pharma Inc - EV/EBITDA Multiple|MIRA - EV/EBITDA Multiple|Flora Growth Corp. (FLGC) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation IMCC|Enterprise Value to EBITDA Ratio ADIL|ARTL: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Ensysce Biosciences (ENSC)|GNLN: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple INM (InMed Pharmaceuticals)|Business Value to Operating Income Before Depreciation AKAN|Enveric Biosciences, Inc. - EV/EBITDA Multiple|BGXX - EV/EBITDA Multiple|Hempacco (HPCO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization